Legend Biotech Corporation

Legend Biotech Corporation is a global, commercial-stage biotechnology company dedicated to developing and manufacturing innovative cell therapies, primarily focused on oncology. The company's mission is to transform lives through these therapies, aiming to become a global leader in cell and gene therapy by pursuing cures for intractable diseases. Its global corporate headquarters are located in Bridgewater, New Jersey.

Legend Biotech's key product is CARVYKTI® (ciltacabtagene autoleucel), a one-time CAR-T cell therapy for relapsed or refractory multiple myeloma, co-developed and commercialized in partnership with Johnson & Johnson. The company's pipeline includes a broad portfolio of autologous and allogeneic CAR-T, CAR-NK, and gamma-delta (γδ) T cell therapies targeting various hematologic malignancies and solid tumors.

In recent news, Legend Biotech announced the pricing of an underwritten public offering of American Depositary Shares in June 2026, expected to generate approximately $226 million in gross proceeds. The company also recently established clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T, in relapsed/refractory B-cell non-Hodgkin lymphoma. With over 3,000 employees, Legend Biotech positions itself as the largest standalone cell therapy company and a pioneer in advancing cancer care.